Arbutus Biopharma (ABUS) came out with a quarterly loss of $0.07 per share versus the Zacks Consensus Estimate of a loss of $0.08. This compares to loss of $0.12 per share a year ago. These ...

WARMINSTER, Pa., March 27, 2025 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage ...

Arbutus Biopharma and Genevant Sciences are broadening the scope of their patent infringement claims against Moderna with five new international lawsuits. It’s the latest development in a bitter ...

WARMINSTER, Pa., March 27, 2025 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) ("Arbutus” or the "Company”), a clinical-stage biopharmaceutical company focused on infectious disease, ...

Genevant and Arbutus are seeking monetary relief and injunctions against Spikevax® and, where applicable, additional Moderna products that Moderna has represented use the same LNP technology ...

Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of ...

Arbutus is also exiting its corporate headquarters in Pennsylvania and will terminate all in-house scientific research. The company’s focus is now an RNAi asset for hepatitis B. Arbutus Biopharma is ...

We apologize, but this video has failed to load.

Roivant Sciences (Nasdaq: ROIV) portfolio company Genevant Sciences and Canada’s Arbutus Biopharma (Nasdaq: ABUS) yesterday filed five international lawsuits seeking to enforce patents protecting ...

March 03, 2025 (GLOBE NEWSWIRE) -- Genevant Sciences, a leading nucleic acid delivery company with world-class platforms and a robust lipid nanoparticle (LNP) patent portfolio (a subsidiary of Roivant ...